Henderson's Burvill tops up on AstraZeneca post-Pfizer bid

Henderson's Chris Burvill is buying AstraZeneca, among other firms, in a move to benefit from merger and acquisition speculation.

The director of UK equities and manager of the £1.7bn Cautious Managed fund is a long-time holder of AstraZeneca, but has been buying up the stock on share price weakness following a failed bid by US peer Pfizer. AstraZeneca’s shares dropped as much as 15% last Monday when the management rejected a ‘final’ bid which valued the company at £69bn. Burvill suggested a takeover could still happen at some point in the future, however. “There is a small possibility Pfizer and AstraZeneca will manage to agree something. The difference between the current share price and the Pfizer offer is...